Vol. 2 No. 2 (2022)
Reimbursement Recommendations

Sacituzumab Govitecan (Trodelvy)

Published February 11, 2022

Key Messages

  • CADTH recommends that Trodelvy should be reimbursed by public drug plans for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior therapies, at least 1 of them for metastatic disease if certain conditions are met.
  • Trodelvy should only be covered to treat patients with triple-negative breast cancer that has spread to other parts of the body or cannot be removed by surgery, and who have received 2 or more prior treatments, including at least 1 treatment for metastatic disease; and have good performance status.
  • Trodelvy should only be reimbursed if it is prescribed by a clinician who is experienced in treating cancer. The price of Trodelvy must be lowered to be cost-effective and affordable.